EANS-News: Oxygen Biotherapeutics Introduces Dermacyte® Oxygenating Eye Complex,an Oxygen-rich Serum to Reduce the Appearance of Fine Lines Around Eyes

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

New Products/Biotechnology

Durham, NC (euro adhoc) - DURHAM, NC, July 28, 2010 — Oxygen
Biotherapeutics, Inc. (NASDAQ & SIX Swiss Exchange: OXBT) today
introduced its new, innovative skin care product, DERMACYTE®
Oxygenating Eye Complex, a smooth, delicate eye serum specially
designed to refresh, hydrate and restore the appearance of youth to
the eye contour area. Beginning August 9th, retail orders can be
placed on Oxygen Biotherapeutics´ secure website at
www.BuyDermacyte.com. Orders made by August 31st can receive free
shipping in the U.S. and Canada by using the Code SHIPCOMPLEX10.

"The market to diminish the appearance of fine lines and wrinkles
continues to grow as the last of the Baby Boomers nears 50 and
Generations X & Y enter their 30´s and 40´s. We believe our
oxygen-carrier skin care line is an excellent alternative to existing
products and procedures, and we intend to market and sell our
products on-line, with an internal sales force and distributors, and
through partners," said Maria Isabel Tamargo, Assistant Vice
President of Marketing and Sales.

DERMACYTE Oxygenating Eye Complex is an enriched oxygen emollient
developed by the makers of oxycyte technology (an oxygen carrier). It
is infused with avocado essence, soothing oat kernel, seed extract
from the meadowfoam plant, Vitamin C, sunflower oil and calming high
ash. These ingredients help improve hydration and prevent water loss,
while protecting your skin against environmental stress, flakiness,
dryness, discoloration and puffiness in the eye area. It is
hypoallergenic, paraben-free and reinforces skin firmness and tone
around the eye area. It is available in a 15 ml pump bottle that
allows you to carefully dispense only the small amount needed for
your eye area. The cost is $120.

Oxygen Benefits Your Skin Oxygen is essential for radiant,
young-looking skin. It assists in the production of collagen and
elastin, as well as with skin repair and regeneration. As we age,
the body´s ability to deliver oxygen to dermal tissue deteriorates. A
lack of oxygen at the cellular level can cause skin to age
prematurely, increasing the appearance of fine lines and age spots,
making skin look dry and dull. Oxygen therapies enhance the overall
appearance and feel of your skin, leaving it smoother and
healthier-looking.

About Oxygen Biotherapeutics, Inc. Oxygen Biotherapeutics, Inc. is
developing medical and cosmetic products that efficiently deliver
oxygen to tissues in the body. The Company has developed a
proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and
liquid ventilation product called Oxycyte® that is being formulated
for both intravenous and topical delivery for conditions including
but not limited to traumatic brain injury, decompression sickness and
topical wounds, as well as for personal skin care. More information
is available at www.oxybiomed.com.

Caution Regarding Forward-Looking Statements This news release
contains certain forward-looking statements by the company that
involve risks and uncertainties and reflect the company's judgment as
of the date of this release. These statements include those referring
to the plans for the expansion of the Dermacyte product line and the
timing of the introduction of those new products. Matters beyond the
company´s control could lead to delays in the new product
introductions and customer acceptance of these new products.
Furthermore, there can be no assurance that such plans will lead to
meaningful sales of Dermacyte or generate any revenue for the
company. The company disclaims any intent or obligation to update
these forward-looking statements beyond the date of this release.
This caution is made under the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Oxygen Biotherapeutics Inc.
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Ellen Corliss

Vice President, Corporate Communications

& Investor Relations

Oxygen Biotherapeutics, Inc

2530 Meridian Pkwy, 3rd floor

Durham, NC 27713

Direct Telephone: +1 919 806 4405

Direct Fax: +1 919 806 4417

Email: e.corliss@oxybiomed.com

Branche: Biotechnology
ISIN: US69207P2092
WKN: 10728277
Index: SSIRT
Börsen: New York / Nasdaq
SIX Swiss Exchange / Main Standard